Merck & Company Inc. Company Profile
NYSE: MRKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:03 PM ET · Delayed 15 min
Merck at a glance
Merck & Company Inc. (NYSE: MRK) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Rahway, NJ. Merck is led by Mr. Robert M. Davis J.D. and employs about 73,000 people. At a market capitalization of $352.29 billion, it ranks among the largest companies in the US market.
MRK is a member of the SP500, DJIA. Its SEC Central Index Key (CIK) is 0000310158, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Merck do?
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Business description based on the company's public filings.
Company information
- Legal name
- Merck & Company Inc.
- Ticker
- NYSE: MRK
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert M. Davis J.D.
- Employees
- 73,000
- Headquarters
- 126 East Lincoln Avenue, Rahway, NJ, United States
- Phone
- 908 740 4000
- Website
- merck.com
- Market cap
- $352.29B
- SEC CIK
- 0000310158
- Latest annual report
- 10-K · Feb 24, 2026
Index membership
Companies similar to Merck
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVSNovartis AG | 143.11 | -0.12% | $272.01B | vs MRK |
| AZNAstraZeneca PLC | 158.78 | -0.84% | $246.25B | vs MRK |
| ABBVAbbVie Inc. | 272.42 | +0.39% | $481.40B | vs MRK |
| ABTAbbott Laboratories | 98.49 | -0.24% | $170.43B | vs MRK |
| NVONovo Nordisk A/S | 38.18 | -0.21% | $168.54B | vs MRK |
| PFEPfizer Inc. | 27.82 | -0.64% | $158.56B | vs MRK |
| VRTXVertex Pharmaceuticals Incorporated | 503.25 | -0.47% | $127.55B | vs MRK |
| BMYBristol-Myers Squibb Company | 59.58 | -0.20% | $121.70B | vs MRK |